ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY
Yıl: 2022 Cilt: 5 Sayı: 3 Sayfa Aralığı: 181 - 187 Metin Dili: İngilizce DOI: 10.53446/actamednicomedia.1109338 İndeks Tarihi: 06-12-2022
ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY
Öz: Objective: We aimed to review clinical, laboratory findings, disease progression and treatment response in patients with isolated polymyalgia rheumatica (PMR) and to investigate the effect of initial and maintenance corticosteroid dose on the disease progression. Methods: Nineteen isolated PMR patients were included in the study. Demographic data, anthropometric measurements, comorbidities, initial symptom, physical examination, clinical, laboratory findings, medications, changes in treatment status, cumulative corticosteroid dose were recorded. The medical data of first (1st month), second (4th month), third (7th month) visits were noted. Results: The initial corticosteroid dose was 21.5±8.9 mg. While the complaints regarding PMR decreased in 52.6% of patients in the first visit, those complaints regressed in 47.4% and 73.7% of patients in the second and third visit, respectively. In the first visit, the mean erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) values were 21.7±12.3 mm/h and 5.8±5.1 mg/dl. In the second and third visits, while the mean ESR was found as 36.5±27.3 mm/h and 27.3±18.6 mm/h, the mean CRP was 27.2±43.0 mg/dl and 17.6±30.2 mg/dl, respectively. Clinical remission was observed in 47.4% of patients in the second visit and in 31.6% of patients in the third visit. Median cumulative corticosteroid doses were 600 mg in first visit, 960 mg in second visit and 1346 mg in the third visit. Conclusion: The clinical characteristics and the initial corticosteroid dose were compatible with the literature. Even though cumulative corticosteroid doses were quite high, lower remission rates were observed in these patients.
Anahtar Kelime: İZOLE POLİMYALJİA ROMATİKA HASTALARININ KLİNİK İZLEMİ: TEK MERKEZLİ, RETROSPEKTİF KOHORT ÇALIŞMASI
Öz: Amaç: Bu çalışmada izole polimyaljia romatika (PMR) tanılı hastaların klinik durum, laboratuvar bulguları, hastalık seyri ve tedavi yanıtlarının kısa dönem verilerinin taranması ve kortizon başlangıç ve idame dozunun hastalık progresyonuna etkisinin incelenmesini amaçladık. Yöntem: On dokuz izole PMR hastası çalışmaya dahil edildi. Hastaların demografik verileri, antropometrik ölçümleri, ek hastalıkları, şikayetleri, fizik muayene bulguları, klinik bulguları, laboratuvar bulguları, tedavileri, tedavi değişiklikleri, kümülatif kortizon dozları kaydedildi. Hastaların 1. ay, 4. ay ve 7. ay poliklinik kontrollerinde elde edilen medikal kayıtları bir olgu formu yardımı ile not edildi. Bulgular: Hastaların ortalama kortizon başlangıç dozu 21,5±8,9 mg idi. Birinci poliklinik kontrolünde, hastaların %52,6’sının şikayetleri tamamen gerilerken, bu oran 2. ve 3. poliklinik kontrolünde sırası ile %47,4 ve %73,7 idi. Birinci poliklinik kontrolü ortalama eritrosit sedimentasyon hızı (ESH) ve C-reaktif protein (CRP) değerleri sırası ile 21,7±12,3 mm/saat ve 5,8±5,1 mg/dl idi. İkinci ve 3. poliklinik kontrolünde ortalama ESH değerleri sırası ile 36,5±27,3 mm/saat ve 27,3±18,6 mm/saat iken ortalama CRP değerleri sırası ile 27,2±43,0 mg/dl ve 17,6±30,2 mg/dl idi. Hastaların takipleri sırasındaki remisyon oranları ise 2. poliklinik kontrolünde %47,4 ve 3. poliklinik kontrolünde %31,6 olarak bulundu. Median kümülatif kortikosteroid dozları 1. poliklinik kontrolünde 600 mg, 2. poliklinik kontrolünde 960 mg ve 3. poliklinik kontrolünde 1346 mg idi. Sonuç: Klinik özellikler ve başlangıç kortikosteroid dozu literatürle uyumluydu. Kümülatif kortikosteroid dozları yüksek olmasına rağmen bu hastalarda daha düşük remisyon oranları gözlendi.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Hunder GG. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. Mayo Clin Proc. 2006;81(8):1071-1083. doi:10.4065/81.8.1071
- 2. Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum. 2004;33(5):289-293. doi:10.1016/j.semarthrit.2003.09.007
- 3. Partington RJ, Muller S, Helliwell T, Mallen CD, Abdul Sultan A. Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study. Ann Rheum Dis. 2018;77(12):1750-1756. doi:10.1136/annrheumdis-2018- 213883
- 4. González-Gay MA, Matteson EL, Castañeda S. Polymyalgia rheumatica. Lancet. 2017;390(10103):1700-1712. doi:10.1016/S0140-6736(17)31825-1
- 5. Masson C, Gonzalez-Gay MA. Polymyalgia rheumatica and giant cell arteritis. In: Bijlsma JWJ, Hachulla E, ed. EULAR Textbook on Rheumatic Diseases. 2nd ed. London, UK: BMJ Publishing Group; 2015:754–778.
- 6. Salvarani C, Cantini F, Macchioni P, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 1998;41(7):1221-1226. doi:10.1002/1529- 0131(199807)41:7<1221::AID-ART12>3.0.CO;2-W
- 7. Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum. 2000;30(1):17-24. doi:10.1053/sarh.2000.8366
- 8. Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799-1807. doi:10.1136/annrheumdis-2015- 207492
- 9. Yates M, Watts RA, Swords F, MacGregor AJ. Glucocorticoid withdrawal in polymyalgia rheumatica: the theory versus the practice. Clin Exp Rheumatol. 2017;35(1):1-2.
- 10. Gonzalez-Gay MA, Agudo M, Martinez-Dubois C, Pompei O, Blanco R. Medical management of polymyalgia rheumatica. Expert Opin Pharmacother. 2010;11(7):1077- 1087. doi:10.1517/14656561003724739
- 11. Yağcı İ. Polymyalgia Rheumatica in 21st Century. Turk J Phys Med Rehab. 2012;58:143- 150.doi:10.4274/tftr.70298
- 12. Charpentier A, Verhoeven F, Sondag M, Guillot X, Prati C, Wendling D. Therapeutic response to prednisone in relation to age in polymyalgia rheumatica: a comparison study. Clin Rheumatol. 2018;37(3):819-823. doi:10.1007/s10067-018-3988-3
- 13. Dejaco C, Duftner C, Cimmino MA, et al. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis. 2011;70(3):447-453. doi:10.1136/ard.2010.133850
- 14. Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol. 2005;32(1):65-73.
- 15. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982;97(5):672-680. doi:10.7326/0003-4819-97-5-672
- 16. Bowness P, Shotliff K, Middlemiss A, Myles AB. Prevalence of hypothyroidism in patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol. 1991;30(5):349-351. doi:10.1093/rheumatology/30.5.349
- 17. Juchet H, Labarthe MP, Ollier S, Vilain C, Arlet P. Prevalence of hypothyroidism and hyperthyroidism in temporal arteritis and rhizomelic pseudopolyarthritis. A controlled study of 104 cases. Rev Rhum Ed Fr. 1993;60(7- 8):493-498.
- 18. Partington R, Helliwell T, Muller S, Abdul Sultan A, Mallen C. Comorbidities in polymyalgia rheumatica: a systematic review. Arthritis Res Ther. 2018;20(1):258. Published 2018 Nov 20. doi:10.1186/s13075-018-1757-y
- 19. Van Hemelen M, Betrains A, Vanderschueren S, Blockmans D. Impact of age at diagnosis in polymyalgia rheumatica: A retrospective cohort study of 218 patients. Autoimmun Rev. 2020;19(12):102692. doi:10.1016/j.autrev.2020.102692
- 20. Lee JH, Choi ST, Kim JS, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int. 2013;33(6):1475-1480. doi:10.1007/s00296-012-2580-4
- 21. Cimmino MA, Parodi M, Montecucco C, Caporali R. The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity. BMC Musculoskelet Disord. 2011;12(1):94. Published 2011 May 14. doi:10.1186/1471-2474-12-94
- 22. Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004;141(7):493-500. doi:10.7326/0003- 4819-141-7-200410050-00005
- 23. Aoki A, Kobayashi H, Yamaguchi Y. Predictors of long-term therapy with glucocorticoid in polymyalgia rheumatica. Mod Rheumatol. 2021;31(2):417-420. doi:10.1080/14397595.2020.1777680
- 24. Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:120638. doi:10.1155/2013/120638
- 25. Helliwell T, Hider SL, Mallen CD. Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice. Br J Gen Pract. 2013;63(610):e361-e366. doi:10.3399/bjgp13X667231
- 26. Yurdakul FD, Bodur H, Sivas F, Başkan B, Eser F, Yılmaz O. Clinical Features, Treatment and Monitoring in Patients With Polymyalgia Rheumatica. Arch Rheumatol 2015;30(1):28-33. doi:10.5606/ArchRheumatol.2015.4643
| APA | Tuncer Kuru F, Gokcen N, Yazici A, Cefle A (2022). ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY. , 181 - 187. 10.53446/actamednicomedia.1109338 |
| Chicago | Tuncer Kuru Fatma,Gokcen Neslihan,Yazici Ayten,Cefle Ayse ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY. (2022): 181 - 187. 10.53446/actamednicomedia.1109338 |
| MLA | Tuncer Kuru Fatma,Gokcen Neslihan,Yazici Ayten,Cefle Ayse ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY. , 2022, ss.181 - 187. 10.53446/actamednicomedia.1109338 |
| AMA | Tuncer Kuru F,Gokcen N,Yazici A,Cefle A ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY. . 2022; 181 - 187. 10.53446/actamednicomedia.1109338 |
| Vancouver | Tuncer Kuru F,Gokcen N,Yazici A,Cefle A ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY. . 2022; 181 - 187. 10.53446/actamednicomedia.1109338 |
| IEEE | Tuncer Kuru F,Gokcen N,Yazici A,Cefle A "ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY." , ss.181 - 187, 2022. 10.53446/actamednicomedia.1109338 |
| ISNAD | Tuncer Kuru, Fatma vd. "ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY". (2022), 181-187. https://doi.org/10.53446/actamednicomedia.1109338 |
| APA | Tuncer Kuru F, Gokcen N, Yazici A, Cefle A (2022). ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY. Acta Medica Nicomedia, 5(3), 181 - 187. 10.53446/actamednicomedia.1109338 |
| Chicago | Tuncer Kuru Fatma,Gokcen Neslihan,Yazici Ayten,Cefle Ayse ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY. Acta Medica Nicomedia 5, no.3 (2022): 181 - 187. 10.53446/actamednicomedia.1109338 |
| MLA | Tuncer Kuru Fatma,Gokcen Neslihan,Yazici Ayten,Cefle Ayse ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY. Acta Medica Nicomedia, vol.5, no.3, 2022, ss.181 - 187. 10.53446/actamednicomedia.1109338 |
| AMA | Tuncer Kuru F,Gokcen N,Yazici A,Cefle A ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY. Acta Medica Nicomedia. 2022; 5(3): 181 - 187. 10.53446/actamednicomedia.1109338 |
| Vancouver | Tuncer Kuru F,Gokcen N,Yazici A,Cefle A ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY. Acta Medica Nicomedia. 2022; 5(3): 181 - 187. 10.53446/actamednicomedia.1109338 |
| IEEE | Tuncer Kuru F,Gokcen N,Yazici A,Cefle A "ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY." Acta Medica Nicomedia, 5, ss.181 - 187, 2022. 10.53446/actamednicomedia.1109338 |
| ISNAD | Tuncer Kuru, Fatma vd. "ISOLATED POLYMYALGIA RHEUMATICA: A CROSS-SECTIONAL, SINGLECENTER, RETROSPECTIVE COHORT STUDY". Acta Medica Nicomedia 5/3 (2022), 181-187. https://doi.org/10.53446/actamednicomedia.1109338 |
